复方银杏叶口服液的制备与临床观察

《复方银杏叶口服液的制备与临床观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、中国医院药学杂志2006年第26卷第7期ChinHospPharmJ,2006Jul,Vol26,No.07841复方银杏叶口服液的制备与临床观察周金彩’，装德新2，王疑芳“(1.永州职业技术学院药学系，湖南永州425006;2.永州职业技术学院附属医院，湖南永州425006;3.永州市冷水滩妇幼保健院，湖南永州425000)〔摘要」目的:配制复方银杏叶口服液并观察其临床疗效。方法:以银杏叶提取物、人参浸青、五味子提取物等组方制成复方银杏叶口服液，高效液相色谱法测定银杏总黄酮醉等;选择174例冠心病患者，采取随机方法分为治疗组(复方银杏叶口服液组)84例，对照

2、组(银杏叶口服液组)90例。结果:本品1ml-含银杏总黄酮醇普不得少于3.6mg;治疗两周后，治疗组与对照组总有效率分别为97.62%和81.110o(P<0.05)。结论:复方银杏叶口服液配方合理、制备工艺简单易行、质量可控;加用复方银杏叶口服液治疗冠心病疗效明显优于加用银杏叶口服液。〔关键词〕复方银杏叶口服液;质量控制;冠心病;临床观察[中图分类号18283.616[文献标识fi]A[文章编号11001-5213(2006)07-0841-03PreparationandclinicalobservationofcompoundGinkgobilobalo

3、ralsolutionZHOUJin-cail，PEIDe-xing2，WANGYi-fang(1.DepartmentofPharmacology,HunanYongzhouVocational-Tech-nicalCollage,HunanYongzhou425006,China;2.TheSubsidaryHospitalofHunanYongzhouVocationalTechnicalCollage,HunanYongzhou425006,China;3.TheWomensandChildrerisHealthCareHospitalofHunanY

4、ongzhouinLensuitan,Hu-nanYongzhou425000,China)ABSTRACLOBJECI'IVEToinvestigatethepreparationmethodandconductclinicalobservationofcompoundGinkgobilobaloralsolution.METHODSCompoundGinkgobilobaloralsolutionwhichwasmadefromGinkgobilobaextract,Ginsengliquidextractive,Chinesemagnoliavineex

5、tract,et.DeterminationofthetotalGinkgoflavoneglycosideswasperformeolbyhighper-formanceliquidchromatography(HPLC).174patientswithcoronaryheartdiseasewererandomlydividedintothetreatmentgroup(84casescompoundGinkgobilobaloralsolutiongroup)andthecontrolgroup(90casesGinkgobilobaloralsolut

6、iongroup).RESULTSCompoundGinkgobilobaloralsolutioncontainsnolessthan3.6mgtotalGinkgoflavoneglycosidespermL;Thetotalefficientratesforthetreatmentgroupandthecontrolgroupwere97.62%oand81.11%respectivelywithintwoweeksaftertreatment(P<0.05).CONCLUSIONTheformulationofcompoundGinkgobilobal

7、oralsolutionisreasonable,thepreparationissimpleandeasytodo,thequalitycanbecontrolled;CompoundGinkgobilobaloralsolutionhasobviouscura-tiveeffectthanGinkgobilobaloralsolutioninthetreatmentofcoronaryheartdisease.KEYWORDS:compoundGinkgobilobaloralliquid;qualitycontrol;coronaryheartdisea

8、se;clinicalobserve银